Wearables encompass the growing range of gadgets that can be attached to the body to measure certain physiological parameters. They are rapidly being adopted in healthcare, as part of a broader health IT revolution, with significant consequences for pharma in both the economics and execution of R&D. There are already an estimated 300 trials underway involving wearables, according to National Institutes of Health data reported in late 2015. Wearables' most immediate potential is in chronic diseases.
This report addresses the following questions:
- What are wearables and how are they impacting pharma?
- Who is developing wearables and what partnerships have pharma companies forged as they venture into this new domain?
- What are the key drivers and resistors to wearables' use in healthcare?
- How has pharma experimented with wearables so far and what are the key takeaways for drug developers?
- What impact have wearables had on pharma R&D so far?
- How will wearables fit within the pharma business model and where is there most potential to generate return on investment from wearables?
Key Topics Covered:
1. What are wearables, and why should pharma care?
2. Wearables makers: pharma partners or competitors?
3. Wearables' early impact in R&D and beyond
4. Drivers and resistors of wearables in healthcare
5. Case studies involve a range of players, devices, and therapy areas
6. Wearables are part of digital health investments
What are Wearables, and Why Should Pharma Care?
7. Wellness and medicine: blurring boundaries
8. Enabling patient centricity; lowering costs
Wearables Makers: Pharma Partners or Competitors?
10. Who is making wearables?
11. Fostering and funding digital health innovation
Wearables' Early Impact in R&D and Beyond
13. Most wearables trials to date have been feasibility studies
Drivers and Resistors of Wearables in Healthcare
Wearables Case Studies
18. Wearables are used along the value chain and across stakeholders
19. Biogen-Google: uncovering the course of multiple sclerosis
20. Novartis-Qualcomm: building the foundations for mobile trials
21. Novartis-Microsoft: measuring multiple sclerosis
22. UCB-MC10: improving diagnosis and treatment of Parkinson's disease
23. Johns Hopkins-Apple: using Apple Watch to predict seizures
24. UnitedHealthcare-Qualcomm: paying for steps
25. Medibio-Medtronic: diagnosing depression
26. Google (Verily)-Dexcom: stick-on glucose monitors for diabetes
27. Otsuka-Proteus Digital Health: digital medicines may improve outcomes but first must pass regulatory muster
Wearables are Part of Digital Health Investments
29. Unquantified investments
30. Efficacy gains expected
31. Who will pay for wearables in healthcare?
32. The technological future, 33. Bibliography
For more information visit http://www.researchandmarkets.com/research/66rbwv/wearables_are
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharma-and-wearables-report-2016---what-are-wearables-and-how-are-they-impacting-pharma---research-and-markets-300301502.html
SOURCE Research and Markets